Using serum glycomics to predict liver cancer recurrence after transplantation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to validate the prognostic value of serum glycomics as biomarkers for disease recurrence in liver transplant recipients diagnosed with hepatocellular carcinoma (HCC). By analyzing specific changes in N-glycan profiles before liver transplantation, the researchers hope to identify patients at higher risk for tumor recurrence and overall mortality. The study will be conducted across multiple centers, enhancing the reliability of the findings. It builds on previous pilot studies that indicated a strong association between glycan changes and HCC outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Signed and dated patient informed consent document
* Diagnosis of hepatocellular carcinoma
* Age ≥ 18 years
* Ability to comply with protocol-specified evaluations and scheduled visits
* Eligible for liver transplantation and/or active on the waiting list for liver transplantation
* Consulted the department of Gastroenterology and Hepatology

Exclusion Criteria:

* Diagnosis of other liver tumors (eg. liver metastasis, cholangiocarcinoma)

Where it's running

• Ghent University Hospital
  Ghent, Belgium Recruiting

Study contacts

• Study coordinator: Xavier Verhelst, MD, PhD
• Email: xavier.verhelst@uzgent.be
• Phone: +32 9 332 23 71

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Immunotherapy for Liver Cancer Patients Before Transplantation

  This study is testing if a new immunotherapy treatment can help liver cancer patients shrink their tumors enough to qualify for a liver transplant.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT05475613

• InstaSure Non-Invasive Finger-Press Test for HCC

  This study tests a non-invasive finger-skin test to help identify hepatocellular carcinoma in adults.

  Recruiting Beijing Municipal Administration of Hospitals · Beijing, Beijing Municipality · NCT07848750

• BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer

  This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.

  Recruiting at 2 sites Phase 3 BeOne Medicines · South Brisbane, Queensland and 1 other locations · NCT07836530

• Zinc add-on with targeted therapy plus immunotherapy for advanced liver cancer

  This study tests whether adding daily zinc to standard targeted therapy and immunotherapy helps people with unresectable or advanced hepatocellular carcinoma.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07793695

• 68Ga-SorB PET/CT imaging for solid tumors

  This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07760012

• Everolimus-based calcineurin-free immunosuppression one year after liver transplant

  This trial tests whether switching to or using everolimus with reduced calcineurin inhibitors after year one post-liver transplant can protect kidney function while maintaining graft health in adults at low rejection risk.

  Recruiting Phase 3 Hannover Medical School · Heidelberg, Baden-Wurttemberg and 15 other locations · NCT07739914

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.